Maryam Mokhtarzadeh
Chief Medical Officer Persephoni Biosciences
Maryam Mokhtarzadeh is Chief Medical Officer at Persephoni, Venture Partner. Headed the Ocular Center of Excellence at Regenxbio and also led in regulatory and strategy building on leadership at AbbVie in clinical development. Leadership roles at the FDA across a decade including in the Office of the Commissioner, CDRH, the Office of Combination Products, and serving as the FDA IRB Chairman. Board-certified Ophthalmologist, with expertise in ophthalmic genetics and corneal transplant. Graduate of Johns Hopkins University School of Medicine and Princeton University.
Seminars
This workshop aims to bring together venture investors and pharmaceutical partnering leaders to provide practical guidance on building compelling investment packages and partnership opportunities. Navigate today’s challenging funding landscape by understanding exactly what venture capitalists and pharmaceutical partners evaluate when considering ophthalmic drug delivery investments.
This workshop will gather experts to discuss:
- Learn what data packages, intellectual property positions, and team capabilities pharma partners require for early-stage deals, including insights from companies that have secured partnerships before entering the clinic
- Discover how to position your program to attract investment in an environment where mega-rounds dominate and capital for smaller raises is increasingly scarce
- Gain strategies for demonstrating your technology’s commercial viability, addressing reimbursement considerations, and articulating clear paths to market that resonate with both investors and strategic partners
- Learn directly from developers who have navigated approvals, regulatory delays, and setbacks to identify the strategies that improve submission success and reduce risk
- Understand common reasons for complete response letters and how to proactively address these issues in your development plan
- Discuss emerging regulatory considerations for novel modalities including gene therapies, cell therapies, and extended-release implants where precedents are still being established
